Allergan Inc. (AGN): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.1%. By the end of trading, Allergan rose $2.63 (2.6%) to $103.76 on heavy volume. Throughout the day, 5,668,859 shares of Allergan exchanged hands as compared to its average daily volume of 2,031,900 shares. The stock ranged in a price between $100.46-$106.56 after having opened the day at $100.88 as compared to the previous trading day's close of $101.13. Other companies within the Health Care sector that increased today were: Alimera ( ALIM), up 62.8%, pSivida ( PSDV), up 35.0%, Oxygen Biotherapeutics ( OXBT), up 18.5% and American Shared Hospital Services ( AMS), up 12.3%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $29.4 billion and is part of the drugs industry. The company has a P/E ratio of 23.4, above the S&P 500 P/E ratio of 17.7. Shares are up 10.2% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Allergan a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, CEL-SCI Corporation ( CVM), down 20.0%, Neogen Corporation ( NEOG), down 8.9%, Esperion Therapeutics ( ESPR), down 8.7% and Relypsa ( RLYP), down 7.1% , were all laggards within the health care sector with Teva Pharmaceutical Industries ( TEVA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Stock Observations; Reviewing Equities: Doug Kass' Views

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Teva's New CEO Brings This Secret Weapon

Will Allergan's Deal With Tribe Hold Up?

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)